Tenax Therapeutics (TENX) Income from Continuing Operations (2010 - 2026)
Tenax Therapeutics (TENX) posted quarterly Income from Continuing Operations of 76400000.0 for Q2 2026, down 604.8% year-over-year from 15134795.32 in Q2 2025, and up 10.77% on a QoQ basis from 85624000.0 in Q1 2026.
Tenax Therapeutics (TENX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Tenax Therapeutics has reported Income from Continuing Operations for 16 years, with the latest figure at 76400000.0 in Q2 2026.
- Income from Continuing Operations for Q2 2026 came in at 76400000.0, down 604.8% year-over-year; the trailing twelve-month figure through Jun 2026 was 204344000.0 (down 549.17% YoY), and the FY2025 annual result was 102949000.0, down 73.66% from the prior year.
- Income from Continuing Operations climbed to 76400000.0 in Q2 2026, from 85624000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 2689942.0 in Q3 2022 and troughed at 85624000.0 in Q1 2026.
- A 5-year average of 13939549.67 and a median of 3879920.0 in 2024 frame the typical range for Income from Continuing Operations.
- The widest annual swing landed in 2022, when Income from Continuing Operations jumped 104.1%; it then plunged 722.52% in 2026.
- A 5-year view of Income from Continuing Operations shows it stood at 2554624.0 in 2022, then sank by 580.63% to 12278314.0 in 2023, then jumped by 48.96% to 6267000.0 in 2024, then sank by 147.82% to 15531000.0 in 2025, then sank by 391.92% to 76400000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 76400000.0 in Q2 2026, 85624000.0 in Q1 2026, and 15531000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Tenax Therapeutics | 78.47 Mn | 78.47 Mn | - | -17.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -76.40 Mn |
| Mar 31, 2026 | -85.62 Mn |
| Dec 31, 2025 | -15.53 Mn |
| Sep 30, 2025 | -26.79 Mn |
| Jun 30, 2025 | -10.84 Mn |
| Mar 31, 2025 | -10.41 Mn |
| Dec 31, 2024 | -6.27 Mn |
| Sep 30, 2024 | -3.96 Mn |
| Jun 30, 2024 | -3.58 Mn |
| Mar 31, 2024 | -3.80 Mn |
| Dec 31, 2023 | -12.28 Mn |
| Sep 30, 2023 | 1.95 Mn |
| Jun 30, 2023 | -1.11 Mn |
| Mar 31, 2023 | -1.41 Mn |
| Dec 31, 2022 | 2.55 Mn |
| Sep 30, 2022 | 2.69 Mn |
| Jun 30, 2022 | 2.60 Mn |
| Mar 31, 2022 | -2.72 Mn |
| Dec 31, 2021 | -62.24 Mn |
| Sep 30, 2021 | 3.45 Mn |